Stocktoria
CNS Pharmaceuticals, Inc. CNSP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-11-08
CNS Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $9.8M | $9.3M | $14.1M | $9.3M | $9.8M |
| Operating income | -$16.0M | -$14.9M | -$18.9M | -$15.3M | -$14.5M |
| Interest expense | — | — | $13,805 | $7,027 | $9,285 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$15.9M | -$14.9M | -$18.9M | -$15.3M | -$14.5M |
| EPS (diluted) | $-35.75 | $-466.89 | $-12509.11 | $-11.22 | $-16.50 |
| Operating cash flow | -$13.8M | -$17.1M | -$14.1M | -$10.6M | -$13.5M |
| Free cash flow | -$13.8M | -$17.1M | -$14.1M | -$10.6M | -$13.5M |
| Cash & equivalents | $7.2M | $6.5M | $548,721 | $10.1M | $5.0M |
| Total assets | $8.6M | $8.7M | $1.7M | $13.1M | $8.8M |
| Total liabilities | $4.1M | $2.5M | $6.1M | $4.9M | $2.6M |
| Shareholders' equity | $4.5M | $6.2M | -$4.4M | $8.1M | $6.2M |
Source: SEC EDGAR filings · CIK 0001729427 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.